Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 diseaseMelanie Ricke‐Hoch, Denise Hilfiker‐Kleiner|PLoS ONE|2021Cited by 89
Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse modelCaroline Schoenherr, Melanie Ricke‐Hoch|Frontiers in Molecular Medicine|2025Cited by 0